Filing summary
Issuer discrepancy: The supplied filing is IKONICS Corporation’s Form 10-Q, not a TeraWulf Inc. filing. It covers the unaudited quarter ended March 31, 2015, with comparisons to the quarter ended March 31, 2014.
Financial results
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Net sales | $3.598 million | $4.465 million |
| Gross profit / margin | $1.101 million / 30.6% | $1.759 million / 39.4% |
| Operating income (loss) | $(471,000) | $315,000 |
| Net income (loss) | $(229,000) | $205,000 |
| Diluted earnings (loss) per share | $(0.11) | $0.10 |
| Operating cash flow | $491,000 | $354,000 |
Sales declined 19.4% year over year. The main driver was a $668,000 decrease in IKONICS Imaging sales; the prior-year quarter benefited from a nonrecurring initial stocking order from a new distributor. Lower Export, Domestic, and DTX sales also weighed on results, partly offset by higher AMS sales. Lower volume and product mix contributed to gross margin compression. SG&A rose to $1.416 million from $1.301 million, including higher health insurance claims and professional-services costs; R&D increased to $156,000 from $143,000.
Balance sheet, cash flow and liquidity
- At March 31, cash and cash equivalents were $1.938 million and short-term investments were $1.861 million. Current assets were $9.152 million and current liabilities $1.490 million.
- Total liabilities were $2.035 million, including $545,000 of deferred income taxes. The company reported no outstanding borrowings; its $1.25 million secured line of credit was unused and due to expire May 31, 2015.
- Operating cash flow was $491,000; capital spending was $376,000. Investing activities used $489,000, including net purchases of certificates of deposit. Cash increased by $2,000 during the quarter.
- Management said existing resources, operating cash flow, and the expected renewal or replacement of the credit line should fund operations and planned investment.
Outlook, risks and notable items
- Management expected 2015 capital expenditures of approximately $930,000 and estimated the AMS building expansion at approximately $3.1 million, with spending expected through the first half of 2016. Expansion-related AMS production costs were expected to pressure near-term gross profit beginning in the second half of 2016.
- Management cited progress in aerospace-related AMS feasibility programs and continued development of DTX products, including applications in prototyping and 3D printing. These initiatives entail execution and commercialization uncertainty.
- The stronger U.S. dollar and weaker European economy adversely affected Export sales; management anticipated continued dollar strength in the near term. Foreign sales were about 31% of sales versus 27% a year earlier. The company had no currency-hedging strategy and said foreign-exchange impacts had not been material.
- The Q1 tax benefit was $240,000, reflecting the net loss; the effective tax benefit rate was 51.2%. Management noted non-deductible items and the domestic manufacturing deduction affected the rate.
- The filing states there were no material changes to previously disclosed risk factors, no legal proceedings, and no off-balance-sheet arrangements. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts to verify
- Confirm the intended issuer and period: this source identifies IKONICS Corporation and Q1 2015, not TeraWulf Inc.
- Review the planned credit-line renewal or replacement ahead of its May 31, 2015 expiration.
- Track sales recovery and margins, especially the effect of the prior-year distributor stocking order, export conditions, and AMS/DTX performance.
- Assess funding and cost risks for the approximately $3.1 million AMS expansion and other planned capital expenditures.
- Consider the filing’s warning that interim results are not necessarily indicative of full-year performance.